ClinConnect ClinConnect Logo
Search / Trial NCT06876597

Motor-Cognitive Interactive Upper Limb Robot Rehabilitation for Post-Stroke Motor Dysfunction

Launched by LIDIAN CHEN · Mar 12, 2025

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Upeer Motor Cognitive Interaction Robot

ClinConnect Summary

This clinical trial is studying a new way to help people recover movement in their arms after having a stroke. Researchers want to see if using a robot that helps with both movement and thinking exercises can improve arm function better than traditional rehabilitation methods. Participants will be divided into three groups: one will use the interactive robot, another will focus only on movement with the robot, and the last group will receive standard rehabilitation. Each training session will last an hour and will take place five times a week for four weeks. The researchers will track how well participants improve and check for any side effects during the study.

To join the trial, participants should be between 40 and 80 years old, have had a stroke that caused weakness in one arm, and be willing to commit to the study. They should also have had their stroke between two weeks and six months ago. However, individuals with certain health issues, severe balance problems, or significant pain may not be eligible. This trial is not yet recruiting participants, but it aims to find the best ways to enhance recovery for stroke survivors using advanced rehabilitation techniques.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Diagnosis of stroke confirmed by CT or MRI.
  • 2. Age between 40 and 80 years, with no gender restrictions.
  • 3. First-ever stroke with unilateral limb paralysis.
  • 4. Onset of stroke between 2 weeks and 6 months prior, with an FMA-UE score of 8-44.
  • 5. Willingness to participate and provide written informed consent.
  • Exclusion Criteria:
  • 1. History of neuromuscular diseases, malignant tumors, or other severe uncontrolled conditions, including cardiac, renal, or hepatic diseases.
  • 2. Seated balance score \< 2, or inability to maintain a sitting position for more than 60 minutes.
  • 3. Modified Ashworth Scale score \> 2.
  • 4. Visual Analog Scale (VAS) score \> 3 for hemiplegic shoulder pain.
  • 5. Boston Diagnostic Aphasia Examination score \< 3.
  • 6. Severe visual impairment preventing participation in upper limb robot-assisted rehabilitation training.
  • 7. Hamilton Depression Scale score \>17, indicating moderate to severe depressive symptoms.
  • 8. Participation in other clinical trials that may interfere with the results of this study.

About Lidian Chen

Lidian Chen is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, Lidian Chen oversees the design, implementation, and management of clinical trials across various therapeutic areas. The organization collaborates with leading research institutions and healthcare professionals to ensure high-quality data collection and analysis, fostering a culture of transparency and collaboration. Lidian Chen is driven by a mission to contribute to the development of safe and effective treatments that address unmet medical needs, ultimately enhancing the quality of life for patients worldwide.

Locations

Fuzhou, , China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported